JP5923493B2 - 注射可能なデポー組成物の調製方法 - Google Patents
注射可能なデポー組成物の調製方法 Download PDFInfo
- Publication number
- JP5923493B2 JP5923493B2 JP2013512880A JP2013512880A JP5923493B2 JP 5923493 B2 JP5923493 B2 JP 5923493B2 JP 2013512880 A JP2013512880 A JP 2013512880A JP 2013512880 A JP2013512880 A JP 2013512880A JP 5923493 B2 JP5923493 B2 JP 5923493B2
- Authority
- JP
- Japan
- Prior art keywords
- risperidone
- days
- polymer
- drug
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 273
- 238000000034 method Methods 0.000 title claims description 47
- 229920000642 polymer Polymers 0.000 claims description 175
- 229960001534 risperidone Drugs 0.000 claims description 173
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 156
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 36
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 31
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 19
- 239000004310 lactic acid Substances 0.000 claims description 17
- 235000014655 lactic acid Nutrition 0.000 claims description 17
- 229920000249 biocompatible polymer Polymers 0.000 claims description 13
- 229920001577 copolymer Polymers 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 167
- 229940079593 drug Drugs 0.000 description 162
- 230000036470 plasma concentration Effects 0.000 description 140
- 239000007943 implant Substances 0.000 description 135
- 238000009472 formulation Methods 0.000 description 127
- 239000002904 solvent Substances 0.000 description 77
- 230000006870 function Effects 0.000 description 63
- 239000000243 solution Substances 0.000 description 62
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 61
- 229960002428 fentanyl Drugs 0.000 description 61
- 238000002347 injection Methods 0.000 description 51
- 239000007924 injection Substances 0.000 description 51
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 50
- 229960003881 letrozole Drugs 0.000 description 50
- 241000283977 Oryctolagus Species 0.000 description 40
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 39
- 229960005017 olanzapine Drugs 0.000 description 38
- 238000011587 new zealand white rabbit Methods 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000002207 metabolite Substances 0.000 description 22
- 230000001225 therapeutic effect Effects 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 20
- 238000007918 intramuscular administration Methods 0.000 description 17
- 239000000872 buffer Substances 0.000 description 16
- 238000009792 diffusion process Methods 0.000 description 16
- 210000000548 hind-foot Anatomy 0.000 description 16
- 239000008363 phosphate buffer Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 14
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 229940071643 prefilled syringe Drugs 0.000 description 12
- 229960004136 rivastigmine Drugs 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000002798 spectrophotometry method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- 239000011859 microparticle Substances 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 238000011065 in-situ storage Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- 239000003021 water soluble solvent Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229960003616 bemiparin Drugs 0.000 description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940004157 risperidone 25 mg Drugs 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000135164 Timea Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- 238000013267 controlled drug release Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229960004323 rivastigmine tartrate Drugs 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100001081 no carcinogenicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940080131 olanzapine 10 mg Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382153.4 | 2010-05-31 | ||
| EP10382153.4A EP2394663B1 (en) | 2010-05-31 | 2010-05-31 | Compositions for injectable in-situ biodegradable implants |
| PCT/EP2011/059001 WO2011151356A2 (en) | 2010-05-31 | 2011-05-31 | Methods for the preparation of injectable depot compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013527213A JP2013527213A (ja) | 2013-06-27 |
| JP2013527213A5 JP2013527213A5 (enExample) | 2014-09-11 |
| JP5923493B2 true JP5923493B2 (ja) | 2016-05-24 |
Family
ID=43301929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013512880A Active JP5923493B2 (ja) | 2010-05-31 | 2011-05-31 | 注射可能なデポー組成物の調製方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10058504B2 (enExample) |
| EP (2) | EP2394663B1 (enExample) |
| JP (1) | JP5923493B2 (enExample) |
| CN (1) | CN102933234A (enExample) |
| BR (1) | BR112012030707A2 (enExample) |
| CA (1) | CA2800641C (enExample) |
| CY (1) | CY1124783T1 (enExample) |
| DK (1) | DK2582395T3 (enExample) |
| EA (1) | EA024211B1 (enExample) |
| ES (2) | ES2897976T3 (enExample) |
| FI (1) | FI2582395T3 (enExample) |
| HR (2) | HRP20211853T1 (enExample) |
| HU (3) | HUE057236T2 (enExample) |
| LT (2) | LT2394663T (enExample) |
| MX (1) | MX346167B (enExample) |
| PL (2) | PL2394663T3 (enExample) |
| PT (2) | PT2394663T (enExample) |
| RS (2) | RS64451B1 (enExample) |
| SI (2) | SI2394663T1 (enExample) |
| SM (2) | SMT202100679T1 (enExample) |
| WO (1) | WO2011151356A2 (enExample) |
| ZA (1) | ZA201209394B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| EP2394664B1 (en) | 2010-05-31 | 2016-06-01 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsychotic injectable depot composition |
| ES2390439B1 (es) * | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | Composición inyectable |
| EP2529756B1 (en) * | 2011-05-31 | 2021-05-19 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidone and/or Paliperidone implant formulation |
| SI2394663T1 (sl) | 2010-05-31 | 2022-02-28 | Laboratorios Farmaceuticos Rovi, S.A. | Sestave za injicirane biološko razgradljive vsadke in situ |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| SI2529757T1 (sl) * | 2011-05-31 | 2014-05-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija paliperidon implantata |
| US8935726B2 (en) | 2012-05-11 | 2015-01-13 | Comcast Cable Communications, Llc | Generation of dynamic content interfaces |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| WO2014164754A1 (en) | 2013-03-11 | 2014-10-09 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US20170079985A1 (en) | 2015-09-21 | 2017-03-23 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| CN113633609B (zh) * | 2016-09-09 | 2023-08-04 | 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) | 抗寄生虫药物原位固化缓释注射剂及其制备方法 |
| JP7716175B2 (ja) * | 2016-09-23 | 2025-07-31 | デルポー・インコーポレイテッド | 小分子治療剤化合物のための組成物 |
| WO2018070940A1 (en) * | 2016-10-14 | 2018-04-19 | Nanyang Technological University | An injectable composition for localized controlled and sustained delivery system |
| US20190343761A1 (en) | 2016-11-16 | 2019-11-14 | Persica Pharmaceuticals Ltd. | Antibiotic formulations for lower back pain |
| EP3600258A1 (en) | 2017-03-20 | 2020-02-05 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulaitons |
| EP3709970B1 (en) * | 2017-11-16 | 2025-05-14 | Persica Pharmaceuticals Ltd. | Linezolid formulations |
| PE20210047A1 (es) * | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
| EP4366726A1 (en) | 2021-07-06 | 2024-05-15 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
| US12594236B2 (en) | 2021-07-16 | 2026-04-07 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
| WO2023233051A1 (es) | 2022-05-18 | 2023-12-07 | Laboratorios Farmacéuticos Rovi, S.A. | Composiciones inyectables de liberación prolongada para su uso en el tratamiento con risperidona junto a inhibidores de la enzima cyp2d6 |
| WO2025153747A1 (es) | 2024-01-17 | 2025-07-24 | Laboratorios Farmacéuticos Rovi, S.A. | Composiciones y esquemas de dosificación de inhibidores de aromatasa mejorados |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| BE758156R (fr) | 1970-05-13 | 1971-04-28 | Ethicon Inc | Element de suture absorbable et sa |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4523591A (en) | 1982-10-22 | 1985-06-18 | Kaplan Donald S | Polymers for injection molding of absorbable surgical devices |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5620700A (en) | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
| US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| ATE288270T1 (de) | 1993-11-19 | 2005-02-15 | Janssen Pharmaceutica Nv | Mikroverkapselte 1,2-benzazole |
| US5620770A (en) | 1995-06-01 | 1997-04-15 | Superior Environmental Products, Inc. | Fifth wheel insert, laminate composite and method of construction |
| ATE318580T1 (de) | 1996-12-20 | 2006-03-15 | Alza Corp | Gelzusammensetzungen und verfahren |
| KR100289471B1 (ko) * | 1998-01-19 | 2001-09-17 | 김충섭 | 휀타닐계마취제의이식형서방성제제 |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| DE50112157D1 (de) * | 2000-01-11 | 2007-04-19 | Roland Bodmeier | Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel |
| US6604561B2 (en) * | 2000-02-11 | 2003-08-12 | Medical Instill Technologies, Inc. | Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial |
| WO2002038185A2 (en) | 2000-11-13 | 2002-05-16 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
| US6565080B1 (en) | 2001-12-17 | 2003-05-20 | Hewlett-Packard Development Company, L.P. | Imaging media loading guide |
| US7658998B2 (en) * | 2003-01-22 | 2010-02-09 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| WO2004081196A2 (en) | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell- schedule dependent anticancer agents |
| US20050003007A1 (en) | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
| EP1660039B1 (en) | 2003-07-18 | 2016-09-28 | Oakwood Laboratories L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| US8444600B2 (en) * | 2003-09-17 | 2013-05-21 | Jae Sang Park | Replaceable heating cartridge for use with a warming device for medical treatment |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| CA2582374A1 (en) | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| EP1824460B1 (en) * | 2004-11-10 | 2014-12-24 | Tolmar Therapeutics, Inc. | A stabilized polymeric delivery system |
| DE102005031868A1 (de) * | 2005-07-04 | 2007-01-18 | Biotronik Vi Patent Ag | Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung |
| US8852638B2 (en) * | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| SE0600876L (sv) * | 2006-04-20 | 2007-10-21 | Sandvik Intellectual Property | Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form |
| EP2079767B1 (en) * | 2006-10-11 | 2014-08-27 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
| US8076448B2 (en) | 2006-10-11 | 2011-12-13 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
| FR2908775B1 (fr) * | 2006-11-17 | 2012-08-31 | Biomatlante | Hydrogel et ses applications biomedicales |
| EP3202814B1 (en) | 2007-02-15 | 2019-10-16 | Tolmar Therapeutics, Inc. | Low burst poly-(lactide/glycolide) and methods to produce polymers |
| WO2008123456A1 (ja) * | 2007-03-29 | 2008-10-16 | Kyocera Corporation | 携帯無線機 |
| CN101677952B (zh) * | 2007-05-18 | 2012-12-05 | 杜雷科特公司 | 改进的贮库制剂 |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| WO2009060473A2 (en) * | 2007-11-06 | 2009-05-14 | Panacea Biotec Limited | Injectable compositions, processes and uses thereof |
| US8629172B2 (en) * | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| EP2394664B1 (en) | 2010-05-31 | 2016-06-01 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsychotic injectable depot composition |
| ES2390439B1 (es) | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | Composición inyectable |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| EP2529756B1 (en) | 2011-05-31 | 2021-05-19 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidone and/or Paliperidone implant formulation |
| SI2394663T1 (sl) | 2010-05-31 | 2022-02-28 | Laboratorios Farmaceuticos Rovi, S.A. | Sestave za injicirane biološko razgradljive vsadke in situ |
| SI2529757T1 (sl) | 2011-05-31 | 2014-05-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija paliperidon implantata |
-
2010
- 2010-05-31 SI SI201032097T patent/SI2394663T1/sl unknown
- 2010-05-31 PL PL10382153T patent/PL2394663T3/pl unknown
- 2010-05-31 HU HUE10382153A patent/HUE057236T2/hu unknown
- 2010-05-31 EP EP10382153.4A patent/EP2394663B1/en active Active
- 2010-05-31 SM SM20210679T patent/SMT202100679T1/it unknown
- 2010-05-31 LT LTEP10382153.4T patent/LT2394663T/lt unknown
- 2010-05-31 ES ES10382153T patent/ES2897976T3/es active Active
- 2010-05-31 HR HRP20211853TT patent/HRP20211853T1/hr unknown
- 2010-05-31 PT PT103821534T patent/PT2394663T/pt unknown
-
2011
- 2011-05-31 DK DK11723441.9T patent/DK2582395T3/da active
- 2011-05-31 PL PL11723441.9T patent/PL2582395T3/pl unknown
- 2011-05-31 JP JP2013512880A patent/JP5923493B2/ja active Active
- 2011-05-31 ES ES11723441T patent/ES2950857T3/es active Active
- 2011-05-31 FI FIEP11723441.9T patent/FI2582395T3/fi active
- 2011-05-31 HR HRP20230890TT patent/HRP20230890T1/hr unknown
- 2011-05-31 EP EP11723441.9A patent/EP2582395B1/en active Active
- 2011-05-31 WO PCT/EP2011/059001 patent/WO2011151356A2/en not_active Ceased
- 2011-05-31 HU HUE11723441A patent/HUE063623T2/hu unknown
- 2011-05-31 CA CA2800641A patent/CA2800641C/en active Active
- 2011-05-31 PT PT117234419T patent/PT2582395T/pt unknown
- 2011-05-31 EA EA201201570A patent/EA024211B1/ru unknown
- 2011-05-31 CN CN2011800265312A patent/CN102933234A/zh active Pending
- 2011-05-31 MX MX2012013867A patent/MX346167B/es active IP Right Grant
- 2011-05-31 BR BR112012030707A patent/BR112012030707A2/pt not_active Application Discontinuation
- 2011-05-31 SI SI201132088T patent/SI2582395T1/sl unknown
- 2011-05-31 RS RS20230619A patent/RS64451B1/sr unknown
- 2011-05-31 LT LTEPPCT/EP2011/059001T patent/LT2582395T/lt unknown
- 2011-05-31 SM SM20230241T patent/SMT202300241T1/it unknown
-
2012
- 2012-05-31 HU HUE12170362A patent/HUE054922T2/hu unknown
- 2012-05-31 RS RS20140075A patent/RS53205B/sr unknown
- 2012-11-30 US US13/690,707 patent/US10058504B2/en active Active
- 2012-12-11 ZA ZA2012/09394A patent/ZA201209394B/en unknown
-
2018
- 2018-07-11 US US16/032,270 patent/US10195138B2/en active Active
-
2021
- 2021-11-29 CY CY20211101041T patent/CY1124783T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013527213A5 (enExample) | ||
| JP5882993B2 (ja) | 抗精神病薬デポ型注射用組成物 | |
| CA2800641C (en) | Compositions for injectable in-situ biodegradable implants | |
| US11752092B2 (en) | Methods for the preparation of injectable depot compositions | |
| EA031819B1 (ru) | Способ приготовления имплантируемой формы рисперидона или палиперидона | |
| OA16256A (en) | Antipsychotic injectable depot composition. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20140602 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140602 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140717 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150824 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151013 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160107 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160412 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160418 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5923493 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |